Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced that it has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma) for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC).

Under the terms of the agreement, Glenmark receives exclusive rights to develop and commercialize Aumolertinib across its licensed territories: Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the agreement. Hansoh Pharma will receive an upfront payment of low double-digit million USD, followed by potential regulatory and commercial milestone payments possibly cumulating to over US$1 billion, in addition to tiered royalties on net sales in the licensed territories.

"At Glenmark, we remain focused on building a growth-oriented oncology business across high-potential markets. Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets," said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.

Aumolertinib, (marketed as Ameile® in China and Aumseqa® in the United Kingdom and Europe), as a monotherapy, has received marketing authorization from the UK MHRA and is indicated the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor ("EGFR") mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. It has also received approval for four indications in China (second-line T790M mutation, first-line NSCLC EGFR mutated, unresectable Stage III post-chemoradiotherapy, and adjuvant Stage II-IIIB NSCLC). Aumolertinib became Hansoh Pharma's first innovative drug approved in an overseas market and the first China-developed EGFR-TKI to be launched internationally.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1966.05 as compared to the previous close of Rs. 1985.35. The total number of shares traded during the day was 15366 in over 3110 trades.

The stock hit an intraday high of Rs. 1992.20 and intraday low of 1959.15. The net turnover during the day was Rs. 30239465.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 GlenmarkSpecialtySA Collaboration License Distribution Agremeent